Integral Diagnostics has reported a substantial earnings turnaround in FY26, with net profit surging 677 percent to $22.0 million from $2.8 million in the prior year. This dramatic improvement reflects both operational leverage and a return to profitability at scale, signaling that the imaging diagnostics operator has successfully navigated a challenging period and is now delivering shareholder value at a materially different level.
The profit growth was underpinned by solid operational expansion, with revenue rising 26 percent to $788.6 million, while operating EBITDA climbed 30.3 percent to $164.8 million. This tells two stories: the business is growing its top line at a healthy pace, and more importantly, it is converting that growth into earnings with improving operational efficiency. The company conducted over 4 million examinations across its clinic network in the year, serving 1.7 million patients through relationships with 70,000 referrers, underlining the scale and reach of its diagnostic footprint.
For investors, the trajectory matters more than any single quarter. A company that can grow revenue by a quarter while expanding EBITDA by a third, and turn a small profit into a substantial one, is demonstrating the kind of operating leverage that justifies equity ownership. The fact that this improvement has been achieved while the company continues investing in growth, including new greenfield sites across Tasmania, Victoria and South Australia, suggests management is balancing shareholder returns with reinvestment for future expansion.
Integral Diagnostics is also positioning itself as an increasingly conscious operator. The company achieved 93 percent reduction in carbon emissions versus FY24 and now sources 100 percent renewable electricity across its Australian operations, complemented by what it describes as a strong patient NPS score. These shifts are not merely marketing garnish, they reflect a business adapting to stakeholder expectations around environmental and social governance while maintaining its core focus on clinical quality and patient outcomes.
The expansion plan and steady operational momentum suggest the company has room to grow both organically and through further market consolidation in a fragmented sector. Investors should watch how the company manages capital deployment over the next 12 to 18 months, particularly whether it maintains dividend policy, continues to deleverage, and how competition and referral patterns respond to economic headwinds. This announcement is price sensitive and has been flagged by the ASX as material information.
View the full ASX announcement (PDF)
About Integral Diagnostics Limited (ASX: IDX)
Integral Diagnostics Limited is a healthcare services company providing diagnostic imaging services including magnetic resonance imaging, positron emission tomography, computed tomography, mammography, interventional radiology, ultrasound, and radiography. The company serves general practitioners, medical specialists, and allied health professionals across Australia and New Zealand. Founded in 1967, it operates from Melbourne, Australia.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
